BMS and Gilead Agree to Commercialize Atripla in Canada
Companies will share responsibility for funding and promotion strategies for this once-daily, single-tablet product.!--h2>
Bristol-Myers Squibb and Gilead Sciences signed an agreement to commercialize Atripla™ (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) in Canada for adults with HIV-1, subject to Health Canada’s approval. Atripla is the first once-daily, single-tablet regimen for HIV.
This agreement expands the companies’ U.S. joint venture established in December 2004. The companies will together complete regulatory filings in Canada and will share responsibility for commercialization in Canada. As in the U.S., both companies will provide funding and field-based sales representatives to promote Atripla.
Atripla combines Bristol’s Sustiva® (efavirenz) and Gilead’s Truvada® (emtricitabine and tenofovir disoproxil fumarate), itself a fixed-dose reformulation of Gilead’s Viread® and Emtriva®. Atripla is intended as a stand-alone therapy or in combination with other antiretrovirals.
Gilead will record revenues from future net sales of Atripla, and Bristol-Myers Squibb will record revenues at percentages relative to the contribution represented by its individual product.